acquired
Stage
1
Investors
About
Developed surface-modifying polymer technologies (branded Endexo) to reduce thrombosis and biofilm formation on blood-contacting medical devices such as catheters. The company's technology was applied to improve device hemocompatibility and reduce infection and occlusion risk for medical device manufacturers.
Explore Semprus Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.